← All medicines

Cancer medicines

Ibritumomab injection regimen

Independent educational summary · Sources checked November 20, 2026

A radiolabeled antibody regimen used with rituximab for selected lymphomas.

Profile scope: Ibritumomab injection regimen. Confirm the exact product and route; formulations and combination products are not interchangeable.

Possible side effects

Digestive upset, body discomfort, headache, or sleep disturbance may occur.

Serious risks and warning signs

The accompanying rituximab can cause fatal infusion reactions. Delayed, prolonged blood-cell suppression can cause infection or bleeding. Severe skin reactions and later blood cancers have been reported. Long-term follow-up matters.

A question for your healthcare team

How long will blood counts be monitored, and which delayed skin or infection symptoms require immediate contact?

What to do with this information

Discuss persistent or troubling symptoms with your prescriber or pharmacist. For severe breathing difficulty, collapse, a seizure, or inability to wake someone, seek emergency help. Read the linked medicine information for drug-specific instructions, including situations requiring immediate action. For routine treatment changes, consult your prescriber rather than changing your dose on your own. Follow the urgent action instructions above and in the linked medicine information.

Sources

Sources checked November 20, 2026. An original AI-assisted educational summary, not a complete adverse-effect or interaction list. This profile is part of the broader library expansion, not the original prescription-use ranking. Inclusion does not confirm current product availability or mean that risks outweigh benefits. This page has not been independently reviewed by a clinician.